Email updates

Keep up to date with the latest news and content from BMC Pharmacology and BioMed Central.

This article is part of the supplement: 5th International Conference on cGMP: Generators, Effectors and Therapeutic Implications

Open Access Poster presentation

Pharmacokinetic analysis of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in individuals with renal impairment compared to healthy controls

Christian Scheerans*, Martin Blunck, Wolfgang Mueck and Reiner Frey

Author Affiliations

Bayer HealthCare AG, Wuppertal, Germany

For all author emails, please log on.

BMC Pharmacology 2011, 11(Suppl 1):P61  doi:10.1186/1471-2210-11-S1-P61

Published: 1 August 2011

First paragraph (this article has no abstract)

Cinaciquat (CIN) is a guanylate cyclase (sGC) activator that induces cyclic GMP generation and vasodilation preferentially in diseased vessels [1]. CIN has the potential to increase cardiac output in patients with acute decompensated heart failure [2]. CIN is predominantly and rapidly cleared by the liver [3], and thus, it was not expected that the kidney function would have an influence on CIN clearance. Nevertheless, we determined the pharmacokinetics of CIN in individuals with renal impairment and age- and gender-matched healthy volunteers with normal renal function [4].